Clinical Arterial Spin-Labeling MR Imaging to Screen for Typical and Atypical Neurodegenerative Disease in the New Era of Alzheimer Treatment

References

1. 1.↵
   1. Bloudek LM,
   2. Spackman DE,
   3. Blankenburg M, et al

   . Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis 2011;26:627–45 doi:10.3233/JAD-2011-110458 pmid:21694448

   CrossRefPubMed
2. 2.↵
   CMS expands access to beta amyloid PET for medicare beneficiaries. https://www.acr.org/Advocacy-and-Economics/Advocacy-News/Advocacy-News-Issues/In-the-Oct-14-2023-Issue/CMS-Expands-Access-to-Beta-Amyloid-PET-for-Medicare-Beneficiaries#:∼:text=CMS%20Expands%20Access%20to%20Beta%20Amyloid%20PET%20for%20Medicare%20Beneficiaries,-Share&text=The%20Centers%20for%20Medicare%20and,(PET)%20dementia%20care%20use
3. 3.↵
   1. Wolk DA,
   2. Detre JA

   . Arterial spin labeling MRI: an emerging biomarker for Alzheimer’s disease and other neurodegenerative conditions. Curr Opin Neurol 2012;25:421–28 doi:10.1097/WCO.0b013e328354ff0a pmid:22610458

   CrossRefPubMed
4. 4.↵
   1. Riederer I,
   2. Bohn KP,
   3. Preibisch C, et al

   . Alzheimer disease and mild cognitive impairment: integrated pulsed arterial spin-labeling MRI and 18F-FDG PET. Radiology 2018;288:198–206 doi:10.1148/radiol.2018170575 pmid:29762090

   CrossRefPubMed
5. 5.↵
   1. Buxton RB,
   2. Frank LR

   . A model for the coupling between cerebral blood flow and oxygen metabolism during neural stimulation. J Cereb Blood Flow Metab 1997;17:64–72 doi:10.1097/00004647-199701000-00009 pmid:8978388

   CrossRefPubMed
6. 6.↵
   1. Chen Y,
   2. Wolk DA,
   3. Reddin JS, et al

   . Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology 2011;77:1977–85 doi:10.1212/WNL.0b013e31823a0ef7 pmid:22094481

   CrossRefPubMed
7. 7.↵
   1. Musiek ES,
   2. Chen Y,
   3. Korczykowski M, et al

   . Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer’s disease. Alzheimers Dement 2012;8:51–59 doi:10.1016/j.jalz.2011.06.003 pmid:22018493

   CrossRefPubMed
8. 8.↵
   1. Ceccarini J,
   2. Bourgeois S,
   3. Van Weehaeghe D, et al

   . Direct prospective comparison of 18F-FDG PET and arterial spin labelling MR using simultaneous PET/MR in patients referred for diagnosis of dementia. Eur J Nucl Med Mol Imaging 2020;47:2142–54 doi:10.1007/s00259-020-04694-1 pmid:31960098

   CrossRefPubMed
9. 9.↵
   1. Johnson NA,
   2. Jahng GH,
   3. Weiner MW, et al

   . Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005;234:851–59 doi:10.1148/radiol.2343040197 pmid:15734937

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Zhao P,
    2. Zhang B,
    3. Gao S

    . 18[F]-FDG PET study on the idiopathic Parkinson’s disease from several parkinsonian-plus syndromes. Parkinsonism Relat Disord 2012;18(Suppl 1):S60–22 doi:10.1016/S1353-8020(11)70020-7 pmid:22166456

    CrossRefPubMed
11. 11.↵
    1. Cheng L,
    2. Wu X,
    3. Guo R, et al

    . Discriminative pattern of reduced cerebral blood flow in Parkinson’s disease and Parkinsonism-Plus syndrome: an ASL-MRI study. BMC Med Imaging 2020;20:78 doi:10.1186/s12880-020-00479-y pmid:32660445

    CrossRefPubMed
12. 12.↵
    1. Blin J,
    2. Baron JC,
    3. Dubois B, et al

    . Positron emission tomography study in progressive supranuclear palsy. Arch Neurol 1990;47:747–52 doi:10.1001/archneur.1990.00530070035009 pmid:2357154

    CrossRefPubMed
13. 13.↵
    1. Telischak NA,
    2. Detre JA,
    3. Zaharchuk G

    . Arterial spin-labeling MRI: clinical applications in the brain. J Magn Reson Imaging 2015;41:1165–80 doi:10.1002/jmri.24751 pmid:25236477

    CrossRefPubMed
14. 14.↵
    1. Zhu WM,
    2. Neuhaus A,
    3. Beard DJ, et al

    . Neurovascular coupling mechanisms in health and neurovascular uncoupling in Alzheimer’s disease. Brain 2022;145:2276–92 doi:10.1093/brain/awac174 pmid:35551356

    CrossRefPubMed
15. 15.↵
    1. van Dyck CH,
    2. Swanson CJ,
    3. Aisen P, et al

    . Lecanemab in early Alzheimer’s disease. N Engl J Med 2023;388:9–21 doi:10.1056/NEJMoa2212948 pmid:36449413

    CrossRefPubMed
16. 16.↵
    1. Sims JR,
    2. Zimmer JA,
    3. Evans CD, et al

    . TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease. JAMA 2023;330:512–27 doi:10.1001/jama.2023.13239 pmid:37459141

    CrossRefPubMed